



# 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference

Tim Mayleben

PRESIDENT AND CHIEF EXECUTIVE OFFICER

JANUARY 10, 2018



# Safe Harbor

## Forward-Looking Statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical and clinical studies and our research and development programs, our ability to advance ETC-1002 into, and successfully complete, clinical studies, and the timing or likelihood of regulatory filings and approvals are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in the preliminary prospectus supplement and the accompanying prospectus. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors, or representatives, including the underwriters of this offering, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

# Esperion Today – Focused Bempedoic Acid Franchise



Two non-statin, ACLi-based, once-daily, oral LDL-C lowering therapies



Complementary to statins and ezetimibe, SOC oral LDL-C lowering therapies



Agreed upon regulatory pathways to approval with FDA for both products




Experienced Lipid Management Team



Funded through approval, with \$309 million in cash at September 30<sup>th</sup>

# Key Upcoming Milestones

Phase 3 Results Expected Throughout 2018 and NDA Submissions by Q1 2019



# Esperion Business Tailwinds



Clear regulatory pathways established with positive momentum for LDL-C lowering at FDA



Updated treatment goals from ACC/AHA by Q1 2019 will result in more patients eligible for LDL-C lowering therapy



Updated ACC/AHA goals increase demand for complementary, accessible, cost-effective, oral LDL-C lowering therapies to help patients achieve the new treatment goals



Payers drawn to cost-effective, convenient, once-daily, oral LDL-C lowering therapies



Increasing utilization of generic ezetimibe will drive combination pill adoption by 2019



[www.esperion.com](http://www.esperion.com)

